SFI
SYRE icon

Susquehanna Fundamental Investments’s Spyre Therapeutics SYRE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,075
Closed -$306K – 1013
2024
Q1 		$306K Buy
+8,075
New +$234K 0.01% 551

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Susquehanna Fundamental Investments's SYRE Position: Q2 2024 in Review

Susquehanna Fundamental Investments sold out of Spyre Therapeutics (SYRE) in Q2 2024, closing a stake of 8,075 shares — an estimated $306K sold.

Susquehanna Fundamental Investments first reported a position in SYRE in Q1 2024 and held it in 1 quarter. The position peaked at $306K in Q1 2024. 107 funds tracked by Wall St. Rank hold SYRE as of Q2 2024.

  • Susquehanna Fundamental Investments reported no remaining Spyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 8,075 Spyre Therapeutics shares in Q2 2024, an estimated $306K.
  • Susquehanna Fundamental Investments first reported a position in Spyre Therapeutics in Q1 2024 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Spyre Therapeutics position peaked at $306K in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.